title: Anti-leukemic properties of IL-12, IL-23 and IL-27: differences and similarities in the control of pediatric B acute lymphoblastic leukemia.
abstract: B acute lymphoblastic leukemia (ALL) is the most common pediatric hematologic malignancy. Although patient cure has reached an excellent rate, a minority of cases relapse and need novel therapies. IL-12, IL-23 and IL-27 belong to the IL-12 superfamily and exert immunological and anti-tumor functions. The latter can be mediated by activation of immune responses or by the direct activity on cancer cells. Recently, the role of IL-12, IL-23 and IL-27 in the control of pediatric B-ALL has been unveiled. Here, we discuss in a translational perspective the role of IL-12 family cytokines in pediatric B-ALL, highlighting similarities and differences in their mechanisms of action.
authors.affiliation: A.I.R.C. Laboratory of Immunology and Tumors, Department of Experimental and Laboratory Medicine, G. Gaslini Institute, Largo G. Gaslini 5, 16148 Genova, Italy.
authors.forename: Claudia
authors.initials: C
authors.lastname: Cocco
authors.forename: Vito
authors.initials: V
authors.lastname: Pistoia
authors.forename: Irma
authors.initials: I
authors.lastname: Airoldi
mesh_terms: D000818:Animals; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D006801:Humans; D018664:Interleukin-12 / Q000276:immunology / Q000627:therapeutic use*; D053759:Interleukin-23 / Q000276:immunology / Q000627:therapeutic use*; D007378:Interleukins / Q000276:immunology / Q000627:therapeutic use*; D015452:Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / Q000188:drug therapy* / Q000276:immunology
chemical_list: D000970:Antineoplastic Agents; D053759:Interleukin-23; D007378:Interleukins; C464565:MYDGF protein, human; D018664:Interleukin-12